All In Biotech

Drug Trial Radar · NCT07553351

GB06 Phase III Trial for Pediatric Growth Hormone Deficiency

A Multicenter, Randomized, Open-Label, Positive-Controlled Phase III Clinical Trial to Study the Efficacy and Safety of Human Growth Hormone Injection (GB06) in Treating Growth Disorders Caused by Pediatric Growth Hormone Deficiency

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

192

Planned (sponsor's estimate)

Start

Jun 6, 2026

Primary completion

Jul 25, 2028

Study completion Oct 24, 2028

Sponsor

Lead sponsor
Kexing Biopharm Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy and safety of GB06 (a biosimilar of Norditropin®FlexProTM from Novo Nordisk) for the treatment of growth disorders caused by growth hormone deficiency (GHD) in children. It aims to determine whether the annual height velocity (an index of height growth rate) in children diagnosed with GHD after 52 weeks of GB06 intervention is comparable to that of Norditropin®FlexProTM. To achieve this, the participants will administer GB06 or Norditropin®FlexProTM at 0.035mg/kg/day for 52 consecutive weeks.

Conditions

  • Growth Hormone Deficiency (GHD)
  • Growth Hormone Deficiency in Children
  • Growth Hormone Deficiency, Pediatric

Interventions

  • GB06Drug

    GB06 0.035mg/kg/day by subcutaneous injection for 52 weeks

  • Norditropin®FlexProTMDrug

    Norditropin®FlexProTM 0.035mg/kg/day by subcutaneous injection for 52 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual height velocity (AHV) at week 52.Time frame: From enrollment to the end of treatment at 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chengdu Women and Children Central Hospital

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.